top of page

225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy


IDENTIFIER (ClinicalTrials.gov): NCT06736418


DRUG/TREATMENT: 225Ac-ABD147


PHASE: 1A/B


STATUS: Recruiting


SPONSOR: Abdera Therapeutics Inc.





DESCRIPTION:


This is an open-label, Phase 1a/1b, first-in-human study testing a new targeted treatment called 225Ac-ABD147 for people with locally advanced or metastatic small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung. All participants must have previously received platinum-based chemotherapy.


What is 225Ac-ABD147?


225Ac-ABD147 is a DLL3-targeting antibody fragment, a small, engineered piece of an antibody that targets cancer cells with a marker called delta-like ligand 3 (DLL3). It is attached to a special linker-chelator that holds a radioactive particle (Actinium-225) so that a precise dose of radiation can be delivered directly to DLL3-positive cancer cells.


The study has two parts: Phase 1a and Phase 1b.


Phase 1a: Safety, Dosing & Early Signals


Phase 1a is designed to understand:


  • Safety and side effects

  • How the drug moves through the body (PK and biodistribution)

  • Early signs of effectiveness

  • The safest and most appropriate dose levels


A small group of participants will also receive an experimental imaging agent, 111In-ABD147, to help researchers see how the treatment travels and where it binds in the body.


Phase 1b: Expanded Testing at Selected Doses


Phase 1b uses the dose levels identified in Phase 1a to further evaluate:

  • Safety

  • How well the treatment works for SCLC and LCNEC


This phase helps researchers better understand the potential benefit of 225Ac-ABD147 in these cancers.


For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.


CONTACT


Abdera Therapeutics Inc.

EMAIL:  AbderaClinicalTrials@abderatx.com

PHONE: 1 650-434-4093


This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. 




bottom of page